← All countries · Africa
92%
MCV1
2025 · WHO/UNICEF estimate
91%
DTP3
2025 · WHO/UNICEF estimate
76%
IPV complete
2025 · WHO/UNICEF estimate
91%
HepB3
2025 · WHO/UNICEF estimate
299
Measles cases
2024 reported
0
Pertussis (whooping cough) cases
2018 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 92%2025 · WHO/UNICEF estimate | 81.7% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 96%2025 · WHO/UNICEF estimate | 85% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 91%2025 · WHO/UNICEF estimate | 84.6% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 87%2025 · WHO/UNICEF estimate | 82.0% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 76%2025 · WHO/UNICEF estimate | 76.1% | C · weak | |
| MCV1First dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 86.3% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 79%2025 · WHO/UNICEF estimate | 69% | B · good | |
| RCV1First dose of rubella-containing vaccine | 92%2025 · WHO/UNICEF estimate | 86.3% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 91%2025 · WHO/UNICEF estimate | 84.6% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 0%2019 · Administrative (country-reported) | 0% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 91%2025 · WHO/UNICEF estimate | 84.6% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 85.1%2025 · Administrative (country-reported) | 85.1% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 88%2025 · WHO/UNICEF estimate | 85.2% | A · strong | |
| RotaCRotavirus vaccine, complete series | 80%2025 · WHO/UNICEF estimate | 83.0% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2019 · Administrative (country-reported) | 0% | D · poor | |
| MenAMeningococcal A conjugate (meningitis belt) | 0%2019 · Administrative (country-reported) | 0% | D · poor | |
| JEJapanese encephalitis vaccine (countries at risk) | 0%2019 · Administrative (country-reported) | 0% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 85%2024 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 52%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 52%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 2992024 | 14per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 302024 | 1.4per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02017 | 0per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 1792025 | 8.2per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02018 | 0per 1,000,000 total population | D · poor | |
| Diphtheria all countries · vaccine evidence | 02024 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 22025 | 0.1per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 22025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 12023 | 0.1per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02020 | 0per 1,000,000 total population | D · poor | |
| Japanese encephalitis all countries · vaccine evidence | 02018 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 392025 | 1.8per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 1982025 | 9per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (61 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | W1 | General/routine | Live births |
| CHOLERACholera vaccine | 1 | >=Y1 | Risk group(s) · SUBNATIONAL | >=Y1 - In the year under review the country administered cholera vaccines for outbreak response in identified Priority Areas for Multisectoral Intervention (PAMIs) except in one district where preventive doses were administered as part of the Controlled Temperature Chain (CTC) study |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | Surviving infants |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | W10 | General/routine | Surviving infants |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | W14 | General/routine | Surviving infants |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Health workers · SUBNATIONAL | Healthcare Workers in the selected 13 pilot districts (3-year pilot) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +W4 | Health workers · SUBNATIONAL | Healthcare Workers in the selected 13 pilot districts (3-year pilot) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Health workers · SUBNATIONAL | Healthcare Workers in the selected 13 pilot districts (3-year pilot) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | <Y14 | Catch-up children | In 2024, Zambia introduced single aged cohort and single dose schedule. Girls aged 9 years old (in school and out of school). Catch up vaccination for missed girls is provided upto 14 years. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9 | HPV for females only | In 2024, Zambia introduced single aged cohort and single dose schedule. Girls aged 9 years old (in school and out of school). Catch up vaccination for missed girls is provided upto 14 years. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9 | Risk group(s) | For girls living with HIV, six months after 1st dose. For girls living with HIV, 12 months after 2nd dose |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M2 | Risk group(s) | For girls living with HIV, six months after 1st dose. For girls living with HIV, 12 months after 2nd dose |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 3 | +M4 | Risk group(s) | For girls living with HIV, six months after 1st dose. For girls living with HIV, 12 months after 2nd dose |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | This recommended together with a full recommendation on Hepatitis B Vaccination for Health Workers. The Health Worker Vaccination pilot is expected to generate more information for the review of the interim recommendation. | |
| IPVIPV (Inactivated polio vaccine) | 1 | W14 | General/routine | Surviving infants |
| IPVIPV (Inactivated polio vaccine) | 2 | M9 | General/routine | Surviving infants |
| MALARIAMalaria vaccine | 1 | M6 | General/routine · SUBNATIONAL | Surviving Infants in high to moderate transmission (current scope is 83 out of 116 districts) |
| MALARIAMalaria vaccine | 2 | M7 | General/routine · SUBNATIONAL | Surviving Infants in high to moderate transmission (current scope is 83 out of 116 districts) |
| MALARIAMalaria vaccine | 3 | M8 | General/routine · SUBNATIONAL | Surviving Infants in high to moderate transmission (current scope is 83 out of 116 districts) |
| MALARIAMalaria vaccine | 4 | M18 | General/routine · SUBNATIONAL | Surviving Infants in high to moderate transmission (current scope is 83 out of 116 districts) |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) · SUBNATIONAL | Contacts of cases |
| MPOXMpox (monkeypox) vaccine | 2 | +W4 | Risk group(s) · SUBNATIONAL | Contacts of cases |
| MRMR (Measles and rubella) vaccine | 1 | M9 | General/routine | Surviving infants |
| MRMR (Measles and rubella) vaccine | 2 | M18 | General/routine | Surviving infants |
| OPVOPV (Oral polio vaccine) | 1 | M9 | Catch-up children | Surviving infants. A birth dose for OPV (OPV0) is provided upto 13 days, if missed the dose is provided at the age of 9 months (OPV4). |
| OPVOPV (Oral polio vaccine) | 1 | B | General/routine | Surviving infants. A birth dose for OPV (OPV0) is provided upto 13 days, if missed the dose is provided at the age of 9 months (OPV4). |
| OPVOPV (Oral polio vaccine) | 2 | W6 | General/routine | Surviving infants. A birth dose for OPV (OPV0) is provided upto 13 days, if missed the dose is provided at the age of 9 months (OPV4). |
| OPVOPV (Oral polio vaccine) | 3 | W10 | General/routine | Surviving infants. A birth dose for OPV (OPV0) is provided upto 13 days, if missed the dose is provided at the age of 9 months (OPV4). |
| OPVOPV (Oral polio vaccine) | 4 | W14 | General/routine | Surviving infants. A birth dose for OPV (OPV0) is provided upto 13 days, if missed the dose is provided at the age of 9 months (OPV4). |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | W6 | General/routine | Surviving infants |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | W10 | General/routine | Surviving infants |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | W14 | General/routine | Surviving infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W6 | General/routine | Surviving infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | W10 | General/routine | Surviving infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 3 | W14 | General/routine | Surviving infants |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | General/routine | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Adults | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | General/routine | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Adults | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | General/routine | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Adults | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | General/routine | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Adults | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | General/routine | WCBA, pregnant women upon 1st contact |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | WCBA, pregnant women upon 1st contact |
| VITAMINAVitamin A supplements | 1 | M6 | General/routine | 6-59 months |
| VITAMINAVitamin A supplements | 2 | M12 | General/routine | 6-59 months |
| VITAMINAVitamin A supplements | 3 | M18 | General/routine | 6-59 months |
| VITAMINAVitamin A supplements | 4 | M24 | General/routine | 6-59 months |
| VITAMINAVitamin A supplements | 5 | M36 | General/routine | 6-59 months |
| VITAMINAVitamin A supplements | 6 | M48 | General/routine | 6-59 months |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.